^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MOCS3 (Molybdenum Cofactor Synthesis 3)

    i
    Other names: MOCS3, Molybdenum Cofactor Synthesis 3, UBA4, Adenylyltransferase And Sulfurtransferase MOCS3, Ubiquitin-Like Modifier Activating Enzyme 4, Molybdenum Cofactor Synthesis Protein 3, Molybdopterin Synthase Sulfurylase, MPT Synthase Sulfurylase, DJ914P20.3, UBA4, Ubiquitin-Activating Enzyme E1 Homolog (Yeast), UBA4, Ubiquitin-Activating Enzyme E1 Homolog
    Associations

    News

    Trials
    1year
    Classification of acute myeloid leukemia based on multi-omics and prognosis prediction value. (PubMed, Mol Oncol)
    When combined with high-throughput drug sensitivity testing, UAMOCS can accurately predict sensitivity to azacitidine (AZA) and venetoclax. The UAMOCS system is available as an R package. The UAMOCS system has the potential to redefine AML subtypes, enhance prognostic predictions, and guide treatment strategies based on patients' immune status and expected responses to therapies.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • MOCS2 (Molybdenum Cofactor Synthesis 2) • MOCS3 (Molybdenum Cofactor Synthesis 3)
    |
    Venclexta (venetoclax) • azacitidine
    2years
    Integrative Multi-Omic Analysis for Prognosis Stratification in Acute Myeloid Leukemia (ASH 2023)
    Receptor tyrosine kinase signaling inhibitors (SB505124 and EphB4) might be sensitive to UAMOCS1. Taken together, UAMOCS model was generated that can classify AML patients independently and help develop precise chemotherapeutic strategy for patients with AML in the future.
    Omic analysis
    |
    RUNX1 (RUNX Family Transcription Factor 1) • EPHB4 (EPH receptor B4) • MOCS2 (Molybdenum Cofactor Synthesis 2) • MOCS3 (Molybdenum Cofactor Synthesis 3)
    |
    RUNX1 mutation
    over2years
    Identifying Genetic Signatures Associated with Oncogene-Induced Replication Stress in Osteosarcoma and Screening for Potential Targeted Drugs. (PubMed, Biochem Genet)
    Seven RSGs (TCF7L2, SLC27A4, PCSK5, NOL6, CHCHD4, EIF3B, and SCO1) may be associated with the ORS gene signatures in osteosarcoma. Repaglinide, tacrolimus, sirolimus, cyclosporine, hydrochlorothiazide and the small molecule VU-0365117-1 are potential therapeutic drugs for osteosarcoma.
    Journal
    |
    TCF7L2 (Transcription Factor 7 Like 2) • MOCS3 (Molybdenum Cofactor Synthesis 3) • TCF7 (Transcription Factor 7)
    |
    sirolimus • cyclosporine